A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer

Conditions:   Metastatic Non-small Cell Lung Cancer (NSCLC);   Non-squamous NSCLC Interventions:   Drug: ABP 215;   Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Carboplatin Sponsors:   Amgen;   Parexel Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials